Cargando…
Predictive P-score for treatment ranking in Bayesian network meta-analysis
BACKGROUND: Network meta-analysis (NMA) is a widely used tool to compare multiple treatments by synthesizing different sources of evidence. Measures such as the surface under the cumulative ranking curve (SUCRA) and the P-score are increasingly used to quantify treatment ranking. They provide summar...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520624/ https://www.ncbi.nlm.nih.gov/pubmed/34657593 http://dx.doi.org/10.1186/s12874-021-01397-5 |
_version_ | 1784584707997958144 |
---|---|
author | Rosenberger, Kristine J. Duan, Rui Chen, Yong Lin, Lifeng |
author_facet | Rosenberger, Kristine J. Duan, Rui Chen, Yong Lin, Lifeng |
author_sort | Rosenberger, Kristine J. |
collection | PubMed |
description | BACKGROUND: Network meta-analysis (NMA) is a widely used tool to compare multiple treatments by synthesizing different sources of evidence. Measures such as the surface under the cumulative ranking curve (SUCRA) and the P-score are increasingly used to quantify treatment ranking. They provide summary scores of treatments among the existing studies in an NMA. Clinicians are frequently interested in applying such evidence from the NMA to decision-making in the future. This prediction process needs to account for the heterogeneity between the existing studies in the NMA and a future study. METHODS: This article introduces the predictive P-score for informing treatment ranking in a future study via Bayesian models. Two NMAs were used to illustrate the proposed measure; the first assessed 4 treatment strategies for smoking cessation, and the second assessed treatments for all-grade treatment-related adverse events. For all treatments in both NMAs, we obtained their conventional frequentist P-scores, Bayesian P-scores, and predictive P-scores. RESULTS: In the two examples, the Bayesian P-scores were nearly identical to the corresponding frequentist P-scores for most treatments, while noticeable differences existed for some treatments, likely owing to the different assumptions made by the frequentist and Bayesian NMA models. Compared with the P-scores, the predictive P-scores generally had a trend to converge toward a common value of 0.5 due to the heterogeneity. The predictive P-scores’ numerical estimates and the associated plots of posterior distributions provided an intuitive way for clinicians to appraise treatments for new patients in a future study. CONCLUSIONS: The proposed approach adapts the existing frequentist P-score to the Bayesian framework. The predictive P-score can help inform medical decision-making in future studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-021-01397-5. |
format | Online Article Text |
id | pubmed-8520624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85206242021-10-20 Predictive P-score for treatment ranking in Bayesian network meta-analysis Rosenberger, Kristine J. Duan, Rui Chen, Yong Lin, Lifeng BMC Med Res Methodol Research BACKGROUND: Network meta-analysis (NMA) is a widely used tool to compare multiple treatments by synthesizing different sources of evidence. Measures such as the surface under the cumulative ranking curve (SUCRA) and the P-score are increasingly used to quantify treatment ranking. They provide summary scores of treatments among the existing studies in an NMA. Clinicians are frequently interested in applying such evidence from the NMA to decision-making in the future. This prediction process needs to account for the heterogeneity between the existing studies in the NMA and a future study. METHODS: This article introduces the predictive P-score for informing treatment ranking in a future study via Bayesian models. Two NMAs were used to illustrate the proposed measure; the first assessed 4 treatment strategies for smoking cessation, and the second assessed treatments for all-grade treatment-related adverse events. For all treatments in both NMAs, we obtained their conventional frequentist P-scores, Bayesian P-scores, and predictive P-scores. RESULTS: In the two examples, the Bayesian P-scores were nearly identical to the corresponding frequentist P-scores for most treatments, while noticeable differences existed for some treatments, likely owing to the different assumptions made by the frequentist and Bayesian NMA models. Compared with the P-scores, the predictive P-scores generally had a trend to converge toward a common value of 0.5 due to the heterogeneity. The predictive P-scores’ numerical estimates and the associated plots of posterior distributions provided an intuitive way for clinicians to appraise treatments for new patients in a future study. CONCLUSIONS: The proposed approach adapts the existing frequentist P-score to the Bayesian framework. The predictive P-score can help inform medical decision-making in future studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-021-01397-5. BioMed Central 2021-10-17 /pmc/articles/PMC8520624/ /pubmed/34657593 http://dx.doi.org/10.1186/s12874-021-01397-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Rosenberger, Kristine J. Duan, Rui Chen, Yong Lin, Lifeng Predictive P-score for treatment ranking in Bayesian network meta-analysis |
title | Predictive P-score for treatment ranking in Bayesian network meta-analysis |
title_full | Predictive P-score for treatment ranking in Bayesian network meta-analysis |
title_fullStr | Predictive P-score for treatment ranking in Bayesian network meta-analysis |
title_full_unstemmed | Predictive P-score for treatment ranking in Bayesian network meta-analysis |
title_short | Predictive P-score for treatment ranking in Bayesian network meta-analysis |
title_sort | predictive p-score for treatment ranking in bayesian network meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520624/ https://www.ncbi.nlm.nih.gov/pubmed/34657593 http://dx.doi.org/10.1186/s12874-021-01397-5 |
work_keys_str_mv | AT rosenbergerkristinej predictivepscorefortreatmentrankinginbayesiannetworkmetaanalysis AT duanrui predictivepscorefortreatmentrankinginbayesiannetworkmetaanalysis AT chenyong predictivepscorefortreatmentrankinginbayesiannetworkmetaanalysis AT linlifeng predictivepscorefortreatmentrankinginbayesiannetworkmetaanalysis |